학술논문
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Document Type
article
Author
Cristina Encinas; José-Ángel Hernandez-Rivas; Albert Oriol; Laura Rosiñol; María-Jesús Blanchard; José-María Bellón; Ramón García-Sanz; Javier de la Rubia; Ana López de la Guía; Ana Jímenez-Ubieto; Isidro Jarque; Belén Iñigo; Victoria Dourdil; Felipe de Arriba; Clara Cuéllar Pérez-Ávila; Yolanda Gonzalez; Miguel-Teodoro Hernández; Joan Bargay; Miguel Granell; Paula Rodríguez-Otero; Maialen Silvent; Carmen Cabrera; Rafael Rios; Adrián Alegre; Mercedes Gironella; Marta-Sonia Gonzalez; Anna Sureda; Antonia Sampol; Enrique M. Ocio; Isabel Krsnik; Antonio García; Aránzazu García-Mateo; Joan-Alfons Soler; Jesús Martín; José-María Arguiñano; María-Victoria Mateos; Joan Bladé; Jesús F. San-Miguel; Juan-José Lahuerta; Joaquín Martínez-López; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Source
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-8 (2022)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0–2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.